Antibody Partnering Terms and Agreements - AZTV7/Cable 13, Me-TV 7.2, HSN 7.3, Phoenix-Prescott, AZ

Antibody Partnering Terms and Agreements

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Antibody Partnering Terms and Agreements

http://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 900 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibody deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with antibodies deals announced along with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibody partnering deals signed and announced since January 2009. The chapter is organized by specific antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z ,deal type, stage of development type and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

Report scope

Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

Antibody Partnering Terms and Agreements includes:

Trends in antibody dealmaking in the biopharma industry since 2009
Analysis of antibody deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life antibody deals
Access to over 900 antibody contract documents
The leading antibody deals by value since 2009
Most active antibody dealmakers since 2009
The leading antibody partnering resources

In Antibody Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 antibody deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise antibody rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Antibody Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of antibody deal trends since 2009
Access to headline, upfront, milestone and royalty data
Analysis of the structure of antibody agreements with numerous real life case studies
Comprehensive access to over 900 actual antibody deals entered into by the world's biopharma companies
Detailed access to actual antibody contracts enter into by the leading companies
Insight into the terms included in a antibody agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in antibody dealmaking

2.1. Introduction
2.2. Antibody partnering over the years
2.3. Big pharma antibody dealmaking activity
2.4 Big Biotech antibody dealmaking activity
2.5. Top 10 active antibody dealmakers
2.6. Antibody partnering by deal type
2.7. Antibody partnering by disease type
2.8. Antibody partnering by stage of development
2.9. Partnering by antibody type
2.10. Average deal terms for antibody partnering
2.10.1 Antibody headline values
2.10.2 Antibody upfront payments
2.10.3 Antibody milestone payments
2.10.4 Antibody royalty rates
2.11. The anatomy of antibody partnering
2.11.a. Case study 1: ADMA Biologics- Biotest: December 31 2012
2.11.b. Case study 2: Amgen- AstraZeneca: April 2, 2012

Chapter 3 – Leading antibody deals

3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 – Big pharma antibody deals

4.1. Introduction
4.2. How to use big pharma antibody partnering deals
4.3. Big pharma antibody partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Endo Pharmaceuticals
Fresenius
Gilead Sciences
GlaxoSmithKline

Grifols
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Takeda
Teva
UCB

Chapter 5 – Big Biotech antibody deals

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech antibody partnering company profiles
Alexion Pharmaceuticals
Cangene
Elan
Emergent BioSolutions
Galapagos
Genmab
LFB Group
Morphosys
PDL BioPharma
Regeneron Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum

Chapter 6 – Antibody dealmaking directory with contract documents

6.1. Introduction
6.2. By Company A-Z
Abbott Laboratories
Abbvie
Adimab
ADMA Biologics
Agensys
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Althea Technologies
Amgen
Arana Therapeutics
AstraZeneca
Avecia Biologics
AVEO Pharmaceuticals
Bayer
Bayer Schering Pharma
Biogen Idec

Biotest
Biotest Pharmaceuticals
BioWa
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Therapeutics
Centocor Ortho Biotech
Corgenix Medical
Crucell
Cytodyn
Elan
Eli Lilly
Facet Biotechnology
Fujifilm Diosynth Biotechnologies
GE Healthcare
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
GlycArt
Green Cross
ImmunoCellular Therapeutics
ImmunoGen
Intellect Neurosciences
Intrexon
Janssen Pharmaceutica NV

Johnson & Johnson
Kaketsuken
KaloBios Pharmaceuticals
Kyowa Hakko Kirin
Lexicon Pharmaceuticals
Lonza
Lpath
Mabtech
Macrogenics
Massachusetts Biologic Laboratories
Matsuura
Medarex
Merck and Co
Merrimack Pharmaceuticals
MicroCoat Biotechnologie
Micromet
Millennium
MorphoSys
Neotope
Novartis

Novo Nordisk
Orbimed Advisors
Organon
Ortho-McNeil
Oxford Immunotec
PDL BioPharma
Peregrine Pharmaceuticals
Pfizer
PharmAthene
Progenics Pharmaceuticals
Receptos
Regeneron Pharmaceuticals
Repligen
RIT Oncology
Roche
Sanofi-Aventis
Sanofi-Pasteur
Scripps Research Institute
Seattle Genetics

Servier
Sicor Italy
Sorrento Therapeutics
Spectrum Pharmaceuticals
Stason Pharmaceuticals
Synthetic Biologics
Takeda Pharmaceutical
Targepeutics
TrovaGene
TTFactor
UCB
Ultragenyx Pharmaceuticals
University of Texas
Wyeth
Xencor
Xoma
ZymoGenetics
6.3. By stage of development
Discovery

Preclinical
Phase I
Phase II
Phase III
Marketed
6.4. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Contract service
Co-promotion
Cross-licensing
Development
Equity purchase
Evaluation
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Supply
Termination
6.5. By therapy area

Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Gynaecology
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Respiratory

Chapter 7- By antibody technology type

7.1. Introduction
7.2. Deals by antibody type
Antibodies
Antibody-drug conjugates
Monoclonal antibodies
Murine mAb
Chimeric mAb
Humanized mAb
Human aAb
Polyclonal Antibodies

Chapter 8 – Antibody partnering resource center

8.1. Online antibody partnering
8.2. Antibody partnering events
8.3. Further reading on antibody dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form – Reports

Appendices

Appendix 1- Deals by Company A-Z
Appendix 2- Deals by stage of development
Appendix 3- Deals by deal type
Appendix 4- Deals by therapy area
Appendix 5- Deals by deal type definitions


TABLE OF FIGURES


Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2009
Figure 3: Big pharma – top 50 – antibody deals 2009 to 2014
Figure 4: Big pharma antibody deal frequency – 2009 to 2014
Figure 5: Big biotech antibody deal frequency – 2009 to 2014
Figure 6: Top 10 antibody dealmakers – 2009 to 2014
Figure 7: Antibody partnering by deal type since 2009
Figure 8: Antibody partnering by disease type since 2009
Figure 9: Antibody partnering by oncology target since 2009
Figure 10: Antibody partnering by stage of development since 2009

Figure 11: Antibody partnering by therapeutic antibody type since 2009
Figure 12: Antibody deals with a headline value
Figure 13: Antibody deal headline value distribution, US$million – discovery stage
Figure 14: Antibody deal headline value distribution, US$million – preclinical stage
Figure 15: Antibody deal headline value distribution, US$million – phase I stage
Figure 16: Antibody deal headline value distribution, US$million – phase II stage
Figure 17: Antibody deal headline value distribution, US$million – phase III stage
Figure 18: Antibody deal headline value distribution, US$million – regulatory stage
Figure 19: Antibody deal headline value distribution, US$million – marketed stage
Figure 20: Summary median headline value by stage of development, 2009-2014
Figure 21: Antibody deals with upfront payment values
Figure 22: Antibody deal upfront payment distribution, US$million – discovery stage
Figure 23: Antibody deal upfront payment distribution, US$million – preclinical stage
Figure 24: Antibody deal upfront payment distribution, US$million – phase I stage
Figure 25: Antibody deal upfront payment distribution, US$million – phase II stage
Figure 26: Antibody deal upfront payment distribution, US$million – phase III stage
Figure 27: Antibody deal upfront payment distribution, US$million – regulatory stage
Figure 28: Antibody deal upfront payment distribution, US$million – marketed stage
Figure 29: Summary median upfront payments by stage of development, 2009-2014
Figure 30: Antibody deals with milestone payments
Figure 31: Antibody deal milestone distribution, US$million – discovery stage
Figure 32: Antibody deal milestone distribution, US$million – preclinical stage
Figure 33: Antibody deal milestone distribution, US$million – phase I stage
Figure 34: Antibody deal milestone distribution, US$million – phase II stage
Figure 35: Antibody deal milestone distribution, US$million – phase III stage
Figure 36: Antibody deal milestone distribution, US$million – regulatory stage
Figure 37: Antibody deal milestone distribution, US$million – marketed stage
Figure 38: Antibody deals with royalty rates, %
Figure 39: Antibody deal royalty rate distribution, US$million – discovery stage
Figure 40: Antibody deal royalty rate distribution, US$million – preclinical stage
Figure 41: Antibody deal royalty rate distribution, US$million – phase I stage
Figure 42: Antibody deal royalty rate distribution, US$million – phase II stage
Figure 43: Antibody deal royalty rate distribution, US$million – phase III stage
Figure 44: Antibody deal royalty rate distribution, US$million – regulatory stage
Figure 45: Antibody deal royalty rate distribution, US$million – marketed stage
Figure 46: Summary median royalty rate by stage of development, 2009-2014
Figure 47: Components of the typical antibody deal structure
Figure 48: Top antibody deals by value since 2009
Figure 49: Online partnering resources
Figure 50: Forthcoming partnering events

Read the full report:
Antibody Partnering Terms and Agreements

http://www.reportbuyer.com/countries/north_america/usa/antibody_partnering_terms_agreements.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and AZ-TV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.